BridgeMD
REGN7508 versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults.
EU CTIS ID: 2025-520478-20-00
What this study is testing
To evaluate the efficacy of IV REGN7508 for the prevention of VTE after TKA compared to enoxaparin and apixaban.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Is undergoing a primary elective unilateral TKA .
- Is in good health based on laboratory safety testing as described in the protocol.
- Body weight ≤130 kg at screening visit as described in the protocol.
- Other protocol-defined Inclusion Criteria apply.
You likely can't join if
- Any condition that, as assessed by the investigator, may confound the results of the study or pose an additional risk to the participant by study participation.
- History of bleeding in the 6 months prior to randomization requiring hospitalization or transfusion as described in the protocol.
- History of thromboembolic disease or thrombophilia.
- History of major surgery, including brain, spinal, or ocular, or major trauma within approximately the past 6 months prior to randomization.
- Has an estimated Glomerular Filtration Rate (GFR) of <30 mL/min/1.73 m2 at the screening visit as described in the protocol.
- Other protocol-defined Exclusion Criteria apply.
The study team makes the final eligibility decision.
Where it's taking place
- Israel
- Japan
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Israel; Japan; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.